Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients
Article first published online: 17 SEP 2004
Copyright © 2004 Wiley-Liss, Inc.
Volume 63, Issue 1, pages 1–12, 1 April 2005
How to Cite
Noguchi, M., Itoh, K., Yao, A., Mine, T., Yamada, A., Obata, Y., Furuta, M., Harada, M., Suekane, S. and Matsuoka, K. (2005), Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate, 63: 1–12. doi: 10.1002/pros.20157
- Issue published online: 27 JAN 2005
- Article first published online: 17 SEP 2004
- Manuscript Accepted: 15 JUN 2004
- Manuscript Received: 11 MAY 2004
- Japan Society for the Promotion of Science (Grants-in-Aid for Science Research (B) to MN). Grant Number: 15591721
- prostate cancer;
- cancer vaccine;
- estramustine phosphate
The safety, toxicity, and immunological response of individualized peptide vaccination or human leukocyte antigen (HLA)-A24+ hormone refractory prostate cancer (HRPC) patients in combination with a low dose of estramustine were evaluated.
Sixteen patients with HLA-A24+ HRPC were enrolled in the phase I/II study. Conducted immune monitorings for those patients were peptide-specific cytotoxic T lymphocyte (CTL) precursor analysis by interferon-γ production and peptide-reactive immunoglobulin G (IgG) by an enzyme-linked immunosorbent assay. Clinical responses and quality of life (QOL) outcomes using a self-reported patient questionnaire were also evaluated.
Vaccinations were well tolerated, but all patients developed grade 1 or 2 local redness and swelling at the injection site. There was no significant immunosuppression in most cases when the peptide and a half dose (280 mg/day) of estramustine were administrated. Augmentation of peptide-specific CTL precursors or peptide-specific IgG was observed in 10 of 14 or 7 of 14 patients at 12 weeks (peptide vaccination alone), and in 6 of 8 or 10 of 12 patients at 24 weeks (during the combination therapy), respectively. All 13 patients treated, with the combination therapy, showed a decrease of serum prostate-specific antigen (PSA) level from the baseline, including six patients with a serum PSA level decrease of ≥ 50%. QOL outcomes were not deteriorated during the treatment.
These results might encourage the further evaluation of the combination of peptide vaccination and a low dose of estramustine phosphate for HLA-A24+ HRPC patients. © 2004 Wiley-Liss, Inc.